WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused ...

In Frequency Therapeutics’ short lifetime as a company, it’s had its ups and downs. On Tuesday, during an R&D event day, the company unleashed a slew of announcements that add context to the ...

On July 17, Astellas Pharma announced that it had entered into an agreement with Frequency Therapeutics to co-develop and commercialise FX-322, a regenerative therapy to treat hearing loss. Astellas ...

An experimental regenerative therapy that Frequency Therapeutics was developing to treat a form of hearing loss has failed to beat a placebo in a clinical trial for the second time in two years, ...

Frequency is testing its treatment in people with sensorineural hearing loss who have suddenly lost their hearing or who have a history of chronic noise exposure. (Alex Blăjan/Unsplash) () Frequency ...

Frequency Therapeutics (NASDAQ:FREQ) is reducing its workforce by 55% and abandoning programs in Sensorineural Hearing Loss (SNHL) after FX-322 failed to meet the main goal of a phase 2b study in ...

Do you or someone you know have trouble hearing people clearly? Does it sound like people are mumbling? High-frequency sensorineural hearing loss may be to blame. This type of hearing loss can be ...

Astellas Pharma will partner with Frequency Therapeutics to develop Frequency’s lead candidate—the Phase IIa-bound sensorineural hearing loss regenerative therapeutic FX-322—through a collaboration ...

The genetics responsible for frequency-specific hearing loss have remained elusive until recently, when genetic loci were found that affected high-frequency hearing. Now, a study reports, for the ...

Shape matters, even in hearing. Specifically, it is the shape of the cochlea — the snail-shell-shaped organ in the inner ear that converts sound waves into nerve impulses that the brain deciphers — ...